

*Wild E J, Tabrizi S J. Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol 2017; 16:837-47*—In table 1, the final row and footnote have been updated to reflect that CHDI Foundation's small-molecule huntingtin-lowering programme is currently at the screening stage and that the mechanisms of action, route of delivery, and advantages and disadvantages of the small molecules being investigated remain to be determined.